BioAge Labs, Inc. (NASDAQ:BIOA) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Five analysts give BioAge an average rating of "Moderate Buy" (four buys, one sell) with a 12‑month average price target of $46.25, while individual targets cited in recent notes range from $23 to $60.
• Stock and recent results: Shares opened at $16.79 with a market cap of about $745M and a negative P/E; the company reported Q1 EPS of -$0.72 (beating estimates) on $3.08M revenue but remains unprofitable with analysts forecasting -2.7 EPS for the year.
• Company focus: BioAge is a clinical‑stage biotechnology firm developing therapies for age‑associated diseases using human omics data and machine learning to identify and validate drug targets.

BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) has been given an average rating of "Moderate Buy" by the five analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $46.25.

A number of research firms recently weighed in on BIOA. Morgan Stanley set a $23.00 price target on BioAge Labs in a research note on Wednesday, February 4th. Citigroup upped their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a "buy" rating in a research note on Tuesday, March 10th. Piper Sandler began coverage on BioAge Labs in a research note on Tuesday, January 27th. They set an "overweight" rating on the stock. Oppenheimer began coverage on BioAge Labs in a research note on Wednesday, February 25th. They set an "outperform" rating and a $60.00 price target on the stock. Finally, Needham & Company LLC began coverage on BioAge Labs in a research note on Friday, March 27th. They set a "buy" rating and a $50.00 price target on the stock.

BioAge Labs Price Performance

Shares of NASDAQ:BIOA opened at $16.79 on Monday. The company has a market capitalization of $745.14 million, a price-to-earnings ratio of -7.50 and a beta of 0.99. The business's 50-day moving average is $18.76 and its 200-day moving average is $15.12. BioAge Labs has a 1 year low of $3.67 and a 1 year high of $24.00.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. The company had revenue of $3.08 million for the quarter. BioAge Labs had a negative return on equity of 27.86% and a negative net margin of 896.11%. Analysts anticipate that BioAge Labs will post -2.7 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in BioAge Labs during the 3rd quarter worth approximately $27,000. CWM LLC raised its stake in BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company's stock worth $49,000 after buying an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company's stock worth $54,000 after buying an additional 5,976 shares during the period. Walleye Capital LLC purchased a new stake in shares of BioAge Labs in the second quarter worth approximately $64,000. Finally, Bank of America Corp DE raised its stake in shares of BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company's stock worth $65,000 after purchasing an additional 3,517 shares during the last quarter.

About BioAge Labs

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.